Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Common Equity: 2019-2024

Historic Common Equity for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $422.2 million.

  • Allogene Therapeutics' Common Equity fell 32.00% to $315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.3 million, marking a year-over-year decrease of 32.00%. This contributed to the annual value of $422.2 million for FY2024, which is 17.58% down from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Common Equity is $422.2 million, which was down 17.58% from $512.2 million recorded in FY2023.
  • Allogene Therapeutics' Common Equity's 5-year high stood at $1.1 billion during FY2020, with a 5-year trough of $422.2 million in FY2024.
  • For the 3-year period, Allogene Therapeutics' Common Equity averaged around $533.8 million, with its median value being $512.2 million (2023).
  • In the last 5 years, Allogene Therapeutics' Common Equity spiked by 71.63% in 2020 and then declined by 27.92% in 2022.
  • Allogene Therapeutics' Common Equity (Yearly) stood at $1.1 billion in 2020, then fell by 14.30% to $925.2 million in 2021, then declined by 27.92% to $666.9 million in 2022, then decreased by 23.19% to $512.2 million in 2023, then dropped by 17.58% to $422.2 million in 2024.